Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samer Aboudola

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Current Opinion in Hematology|June 2, 2005
Angiogenesis in lymphoproliferative disorders: a therapeutic target?Samer Aboudola, Ameet R Kini
Human Pathology|August 7, 2004
Tuberculous tenosynovitisSamer Aboudola, Anna Sienko, Roberta B Carey, et al.
American Journal of Clinical Pathology|April 22, 2006
Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysisGurunathan Murugesan, Samer Aboudola, Hadrian Szpurka, et al.
Blood|June 3, 2006
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutationHadrian Szpurka, Ramon Tiu, Gurunathan Murugesan, et al.
The American Journal of Surgical Pathology|January 27, 2007
Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activationSamer Aboudola, Guruanthan Murugesan, Hadrian Szpurka, et al.
Infection and Immunity|February 22, 2003
Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin ASamer Aboudola, Karen L Kotloff, Lorraine Kyne, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Current Opinion in Hematology|June 2, 2005
Angiogenesis in lymphoproliferative disorders: a therapeutic target?Samer Aboudola, Ameet R Kini
Human Pathology|August 7, 2004
Tuberculous tenosynovitisSamer Aboudola, Anna Sienko, Roberta B Carey, et al.
American Journal of Clinical Pathology|April 22, 2006
Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysisGurunathan Murugesan, Samer Aboudola, Hadrian Szpurka, et al.
Blood|June 3, 2006
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutationHadrian Szpurka, Ramon Tiu, Gurunathan Murugesan, et al.
The American Journal of Surgical Pathology|January 27, 2007
Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activationSamer Aboudola, Guruanthan Murugesan, Hadrian Szpurka, et al.
Infection and Immunity|February 22, 2003
Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin ASamer Aboudola, Karen L Kotloff, Lorraine Kyne, et al.
Pageof 1